HETEROCYCLIC COMPOUNDS AS SELECTIVE INHIBITORS OF HUMAN CYTOMEGALOVIRUS
杂环化合物作为人类巨细胞病毒的选择性抑制剂
基本信息
- 批准号:6235030
- 负责人:
- 金额:$ 16.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-08-01 至 1998-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This proposal outlines several specific areas for the development of an
agent to specifically treat HCMV infections. The target compounds will be
elected on the basis of the structure activity relationships which have
already been established from current and previous studies in our
laboratory. Several areas of research are proposed and the specific aims
for the next five years include the following: the synthesis of some
polysubstituted benzimidazoles and imidazoles and their corresponding
nucleosides and nucleoside analogs based on structure activity
relationships derived from structurally related compounds. The synthesize
of a few select 5-bromotubercidin and thiosangivamycin analogs is proposed.
Synthesis of selected polysubstituted benzimidazole carbamates, unrelated
to the above polysubstituted benzimidazoles, using a compound discovered
through our very limited screen involving compounds selected at random from
our previous synthetic investigations, as our focal point. The in vitro
evaluations from Professors Drach, Lopatin and Kern's laboratories will be
used to direct the chemical modifications in each new area of potential
agents. All of these studies should provide some insights into the
modifications which will effect an increase in the selectivity of these
compounds against HCMV.
该提案概述了几个特定领域的开发
专门治疗人巨细胞病毒感染的试剂。目标化合物将是
根据具有以下特征的结构活动关系推选
已经从当前和以前的研究中建立了我们的
实验室。提出了几个研究领域和具体目标
未来五年包括以下内容:综合一些
多取代苯并咪唑和咪唑及其对应的
基于结构活性的核苷及其类似物
从结构上相关的化合物衍生出来的关系。该合成器
提出了几个精选的5-溴杀菌素和硫代血管万古霉素类似物。
非相关多取代苯并咪唑氨基甲酸酯的合成
对上述多取代苯并咪唑,使用一种已发现的化合物
通过我们非常有限的筛选,涉及从
我们之前的综合调查,作为我们的重点。试管苗
来自Drach、Lopatin和Kern教授的实验室的评估将是
用来指导每个新的潜在领域的化学修饰
探员们。所有这些研究都应该为我们提供一些关于
将提高这些化合物的选择性的修改
抗人巨细胞病毒的化合物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
LEROY B. TOWNSEND其他文献
LEROY B. TOWNSEND的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('LEROY B. TOWNSEND', 18)}}的其他基金
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
作为 HCMV 抑制剂的新杂环和核苷
- 批准号:
6651244 - 财政年份:2002
- 资助金额:
$ 16.68万 - 项目类别:
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
作为 HCMV 抑制剂的新杂环和核苷
- 批准号:
6493581 - 财政年份:2001
- 资助金额:
$ 16.68万 - 项目类别:
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
作为 HCMV 抑制剂的新杂环和核苷
- 批准号:
6344678 - 财政年份:2000
- 资助金额:
$ 16.68万 - 项目类别:
HETEROCYCLIC COMPOUNDS AS SELECTIVE INHIBITORS OF HUMAN CYTOMEGALOVIRUS
杂环化合物作为人类巨细胞病毒的选择性抑制剂
- 批准号:
6217095 - 财政年份:1999
- 资助金额:
$ 16.68万 - 项目类别:
HETEROCYCLIC COMPOUNDS AS SELECTIVE INHIBITORS OF HUMAN CYTOMEGALOVIRUS
杂环化合物作为人类巨细胞病毒的选择性抑制剂
- 批准号:
6295676 - 财政年份:1999
- 资助金额:
$ 16.68万 - 项目类别:
NEW HETEROCYCLES AND NUCLEOSIDES AS INHIBITORS OF HCMV
作为 HCMV 抑制剂的新杂环和核苷
- 批准号:
6254606 - 财政年份:1999
- 资助金额:
$ 16.68万 - 项目类别:
HETEROCYCLIC COMPOUNDS AS SELECTIVE INHIBITORS OF HUMAN CYTOMEGALOVIRUS
杂环化合物作为人类巨细胞病毒的选择性抑制剂
- 批准号:
6099541 - 财政年份:1998
- 资助金额:
$ 16.68万 - 项目类别:
NEW INHIBITORS AND NEW TARGETS TO DEVELOP HCMV DRUGS
开发 HCMV 药物的新抑制剂和新靶点
- 批准号:
2066678 - 财政年份:1995
- 资助金额:
$ 16.68万 - 项目类别:
NEW INHIBITORS AND NEW TARGETS TO DEVELOP HCMV DRUGS
开发 HCMV 药物的新抑制剂和新靶点
- 批准号:
2672087 - 财政年份:1995
- 资助金额:
$ 16.68万 - 项目类别:
NEW INHIBITORS AND NEW TARGETS TO DEVELOP HCMV DRUGS
开发 HCMV 药物的新抑制剂和新靶点
- 批准号:
6128094 - 财政年份:1995
- 资助金额:
$ 16.68万 - 项目类别:
相似海外基金
Budding Uninhibited by Benzimidazoles 1の腎臓病進展に与える分子機構の解明
阐明苯咪唑出芽不受抑制1对肾脏疾病进展的分子机制
- 批准号:
23K07700 - 财政年份:2023
- 资助金额:
$ 16.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease
新型苯并咪唑类药物治疗阿尔茨海默病的优化与评价
- 批准号:
10408007 - 财政年份:2021
- 资助金额:
$ 16.68万 - 项目类别:
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease
新型苯并咪唑类药物治疗阿尔茨海默病的优化与评价
- 批准号:
10654786 - 财政年份:2021
- 资助金额:
$ 16.68万 - 项目类别:
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease
新型苯并咪唑类药物治疗阿尔茨海默病的优化与评价
- 批准号:
10745558 - 财政年份:2021
- 资助金额:
$ 16.68万 - 项目类别:
Optimization and evaluation of novel benzimidazoles for the treatment of Alzheimer's Disease
新型苯并咪唑类药物治疗阿尔茨海默病的优化与评价
- 批准号:
10185192 - 财政年份:2021
- 资助金额:
$ 16.68万 - 项目类别:
Rational Design, Synthesis and Biological Evaluation of Benzimidazoles; Towards a Novel Therapy Selectively Targeting C. neoformans beta-tubulin
苯并咪唑类药物的合理设计、合成及生物学评价;
- 批准号:
MR/N023005/1 - 财政年份:2016
- 资助金额:
$ 16.68万 - 项目类别:
Research Grant
Directed ortho metalation approach to C-7-substituted benzimidazoles and indazoles
C-7 取代苯并咪唑和吲唑的定向邻位金属化方法
- 批准号:
424608-2011 - 财政年份:2013
- 资助金额:
$ 16.68万 - 项目类别:
Industrial R&D Fellowships (IRDF)
Directed ortho metalation approach to C-7-substituted benzimidazoles and indazoles
C-7 取代苯并咪唑和吲唑的定向邻位金属化方法
- 批准号:
424608-2011 - 财政年份:2012
- 资助金额:
$ 16.68万 - 项目类别:
Industrial R&D Fellowships (IRDF)
C-7 Functionalisation of Benzimidazoles via Directed C-H Functionalisation
通过定向 C-H 官能化对苯并咪唑进行 C-7 官能化
- 批准号:
425727-2012 - 财政年份:2012
- 资助金额:
$ 16.68万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
BIS-BENZIMIDAZOLES AS ANTI-OPPORTUNISTIC INFECTION AGENTS
双苯并咪唑作为抗机会性感染剂
- 批准号:
3747392 - 财政年份:
- 资助金额:
$ 16.68万 - 项目类别: